Click here to make a Legal complaint

T03-38
May 23, 2003
Media Inquiries: 301-827-6242
Consumer Inquiries: 888-INFO-FDA

FDA Alerts Consumers and Health Professionals to Recall of Counterfeit Lipitor
The Food and Drug Administration (FDA) today announced that Albers Medical Distributors, Inc., has voluntarily recalled three lots of 90-count bottles of the cholesterol-lowering drug Lipitor and is warning healthcare providers and others that these three lots of counterfeit Lipitor represent a potentially significant risk to consumers. The product was repackaged by Med-Pro, Inc., of Lexington, Neb., and the labels say "Repackaged by: MED-PRO, Inc. Lexington, Neb." in the lower left-hand corner.

The following lots are involved in this recall:

20722V - 90-tablet bottles, Expiration 09-2004
04132V - 90-tablet bottles, Expiration 01-2004
16942V - 90-tablet bottles, Expiration 09-2004
FDA is urging healthcare providers and patients alike to check the packaging very carefully before using this product. Patients who have any of the product (labeled as "Repackaged by MED-PRO, Inc.") with these three lot numbers should not take it, and they should return the product to their pharmacies.

As part of the FDA’s ongoing efforts to investigate and address unscrupulous counterfeiting activities, FDA’s Office of Criminal Investigations is investigating the existence of counterfeit Lipitor. Lipitor is a member of a class of cholesterol-lowering drugs that are commonly referred to as "statins."

In carrying out its public health mission, FDA regularly conducts investigations and testing to identify and remove from market products that are counterfeit, have been tampered with, or are otherwise unsuitable.

FDA supports the activities of legitimate manufacturers, in cooperation with FDA, to inform the public about counterfeit products and how to identify them. The agency is committed to rooting out counterfeiting activity and alerting the public to the existence of counterfeit product. Earlier this month, FDA entered into an agreement with a major pharmaceutical trade association to cooperate more closely on cases of suspected counterfeit products.

FDA’s investigation into this matter is continuing.

####

ARAVA AVANDIA BAYCOL BEXTRA DISABILITY ENBREL EPHEDRA FEN-PHEN LARIAM LOTRONEX MERIDIA MEDICAL INSURANCE FRAUD MEDICAL LAWSUITS NORPLANT NURSNG HOME NEGLIGENCE OXYCONTIN PPA PERMAX PREMPRO PROPULSID REMICADE REZULIN RISPERDAL SERZONE SILICOSIS STADOL SULZER STROKE THIMEROSAL MERCURY AUTISM VIOXX WELDING FUMES WRONGFUL DEATH